Gilead Sciences

Gilead Sciences

Organization

Heard in 49 episodes across 19 shows since Jan 2026

Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California. It researches and develops antiviral medicines for HIV/AIDS, hepatitis B and C, influenza, and COVID-19, along with therapies in oncology, inflammation, and cell therapy. The podcast references primarily concern Gilead as a major pharmaceutical company, including debate over the pricing and commercial impact of its highly effective hepatitis C treatments.

Discussed inMarkets94%AI & Tech6%

Episodes

49
across 19 shows

This week

0
episodes on 0 shows

Expert statements

8
7 positive

Share of the conversation

Mentions of Gilead Sciences per 1,000 mentions of anything, 7-day rolling, across the podcasts PodLume Trends follows.

0.0‰0.03‰0.05‰0.07‰0.1‰Aug 25Sep 16Oct 9Oct 31Nov 22
Show the data
DayShare (7-day)Mentions
Sep 130.03‰3
Sep 280.01‰1
Oct 80.02‰2
Oct 100.03‰1
Oct 120.03‰1
Oct 140.05‰2
Oct 190.03‰1
Oct 200.03‰1
Oct 220.02‰1
Oct 230.05‰3
Oct 260.06‰2
Oct 270.07‰3
Oct 290.08‰1
Oct 300.06‰1
Nov 40.03‰2
Nov 60.03‰2
Nov 70.04‰1
Nov 150.02‰3
Nov 200.03‰1

The full trend: rank, tone and why it is trending →

Email alert

Email me when Gilead Sciences comes up on a podcast

One email a week at most, with the new episodes that mention Gilead Sciences. Free, no account needed, unsubscribe in one click.

What experts have said about Gilead Sciences

8 statements · 7 positive · 1 mixed

  1. Daniel CliftonPositiveNov 6, 2026· The Compound and Friends

    Gilead’s hepatitis C cure will save Medicare hundreds of billions of dollars.

    “They are going to save Medicare hundreds of billions of dollars.”

    Listen at 7:10

    Open the episode · You Ain’t Seen Nothing Yet with Daniel Clifton
  2. Yaron WerberMixedNov 6, 2026· Biotech Hangout

    Gilead’s anito-cel is expected to be less effective but safer than Legend’s product.

    “I think it's expected that the Gilead product won't be quite as effective, but a lot safer.”

    Listen at 58:46

    Open the episode · Episode 202 - November 6, 2026
  3. Geoff MeachamPositiveOct 26, 2026· Closing Bell

    Gilead Sciences could perform well in the third quarter.

    “that, I think, could do quite well for 3Q.”

    Listen at 35:53

    Open the episode · Closing Bell Overtime: Markets Face a Big Week as AI Takes Center Stage 10/26/26

Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.

Episodes

49 episodes featuring Gilead Sciences, newest first